NVS - FDA accepts Lantheus' application for generic Lutathera
2024-01-11 09:56:01 ET
More on Lantheus
- Lantheus Stock: Looking To Add After SPLASH's Belly-Flop
- Lantheus: SPLASHdown, Navigating Waves In MCRPC Treatment
- Lantheus Holdings: Huge Catalysts Ahead And Cheap Valuation
- Lantheus says FY23 worldwide revenue is expected to be in the range of $1.295 - 1.297B
- William Blair downgrades Lantheus to market perform
For further details see:
FDA accepts Lantheus' application for generic Lutathera